Natera (NASDAQ:NTRA) Upgraded at BidaskClub

Share on StockTwits

Natera (NASDAQ:NTRA) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday, BidAskClub reports.

Other equities analysts have also issued research reports about the company. Piper Jaffray Companies reissued a “buy” rating on shares of Natera in a research note on Thursday, August 22nd. Craig Hallum increased their target price on Natera from $29.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. Zacks Investment Research raised Natera from a “sell” rating to a “hold” rating in a research note on Friday, August 9th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $38.00 target price on shares of Natera in a research note on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Natera currently has an average rating of “Buy” and an average target price of $32.57.

Natera stock traded up $0.43 during mid-day trading on Thursday, hitting $33.89. The stock had a trading volume of 11,051 shares, compared to its average volume of 608,326. The stock has a 50-day simple moving average of $30.68 and a two-hundred day simple moving average of $24.25. The stock has a market capitalization of $2.37 billion, a PE ratio of -15.78 and a beta of 1.43. Natera has a 12 month low of $11.08 and a 12 month high of $34.53. The company has a current ratio of 2.54, a quick ratio of 2.42 and a debt-to-equity ratio of 1.10.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Wednesday, August 7th. The medical research company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.09. Natera had a negative return on equity of 273.92% and a negative net margin of 46.78%. The business had revenue of $74.36 million for the quarter, compared to analysts’ expectations of $66.77 million. During the same quarter last year, the business earned ($0.62) earnings per share. The firm’s quarterly revenue was up 17.9% compared to the same quarter last year. Sell-side analysts expect that Natera will post -2.1 earnings per share for the current fiscal year.

In other news, Chairman Matthew Rabinowitz sold 1,417 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $29.50, for a total transaction of $41,801.50. Following the sale, the chairman now owns 1,288,164 shares of the company’s stock, valued at $38,000,838. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 98,996 shares of the firm’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $33.00, for a total value of $3,266,868.00. Following the sale, the chief executive officer now directly owns 20,061 shares in the company, valued at approximately $662,013. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 402,642 shares of company stock worth $12,676,686. 9.29% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of NTRA. BNP Paribas Arbitrage SA grew its holdings in shares of Natera by 827.1% during the first quarter. BNP Paribas Arbitrage SA now owns 7,899 shares of the medical research company’s stock worth $163,000 after buying an additional 7,047 shares in the last quarter. NumerixS Investment Technologies Inc grew its holdings in shares of Natera by 86.5% during the first quarter. NumerixS Investment Technologies Inc now owns 13,616 shares of the medical research company’s stock worth $272,000 after buying an additional 6,316 shares in the last quarter. AGF Investments Inc. bought a new position in shares of Natera during the first quarter worth about $1,031,000. MYDA Advisors LLC bought a new position in shares of Natera during the first quarter worth about $722,000. Finally, Marshall Wace LLP bought a new position in shares of Natera during the first quarter worth about $264,000. Institutional investors and hedge funds own 94.95% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Further Reading: How does a security become overbought?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.